Latest Regulatory Development News

Bioxyne expands its LATAM footprint by securing the first international medicinal cannabis flower supply agreement in Costa Rica, with initial shipments valued over $500,000 planned before June 2026.

Macquarie Bank Limited has posted a robust FY2026 result, with net profit attributable to ordinary equity holders soaring 74% to AUD 6.011 billion, underpinned by strong performances in its Banking and Financial Services and Commodities and Global Markets divisions.

Light & Wonder (ASX:LNW) posted modest revenue growth in 2025, driven by Gaming and iGaming segments, while SciPlay revenue dipped slightly. The company completed its Grover acquisition, settled a $128 million IP dispute with Aristocrat, and transitioned to a sole ASX listing.

Mayne Pharma’s third quarter results show modest revenue growth but a sharp improvement in cash flow and earnings, powered by the strong launch of DistributeRx and robust Women’s Health sales.

The FDA has removed the postmarketing cardiac repolarization study requirement for Clinuvel's SCENESSE®, reflecting confidence in its long-term safety profile. This marks a regulatory milestone for the only approved treatment for erythropoietic protoporphyria in the US.

Yancoal Australia posted a record 38.6 million tonnes of attributable saleable coal in 2025, up 5% on 2024, but net profit after tax plunged 64% to A$440 million amid softer coal prices. The miner maintained disciplined cost control and declared A$769 million in fully franked dividends.

Sequoia Financial Group has provided an update on the proposed sale of InterPrac Financial Planning to Conquest Investment Partners, highlighting ASIC’s court action seeking receiver appointment over certain guarantees and ongoing discussions with ASX regarding shareholder approval.

Vmoto Limited forecasts FY26 sales revenue between $73.5 million and $85 million, marking a 57% to 82% increase over FY25, driven by growing orders, strategic partnerships, and regulatory trends favouring electric motorcycles in key markets.

Identitii Limited has secured $200,000 through a placement of approximately 28.57 million shares at $0.007 each to existing shareholders, including Cameron Beavis, to address short-term funding needs while adhering to Takeovers Panel orders related to its Rights Issue.

Xenitra Limited (ASX:XEN) has introduced the OPAL Token and Xen Shop, a blockchain-based digital commerce ecosystem aimed at improving product authentication, customer loyalty, and sales transparency across its Asian FMCG markets.

Fiducian Group Limited has responded to a sharp share price drop by denying any undisclosed information and downplaying the impact of new APRA licence conditions on its operations.

Lumos Diagnostics has secured its largest-ever order for FebriDx® following FDA clearance, signalling a major expansion in the US market opportunity.